Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment?

Why the latest Signatera lymphoma data matters for Natera stock

Natera (NTRA) has become a focus for investors after new real-world data in Blood Neoplasia supported the prognostic and predictive value of its Signatera test for lymphoma patients, reshaping how some view its diagnostics platform.

The study compared Signatera molecular residual disease readings against standard PET/CT scans across newly diagnosed and relapsed or refractory lymphoma cases, using more than 1,100 plasma samples taken from baseline through long term surveillance.

For anyone watching the stock, the interest is less about the medical nuance and more about what this kind of data set implies for test adoption, competitive position and future reimbursement decisions.

Natera’s recent news flow has arrived against a backdrop of strong momentum, with the share price at US$328.18 and a 90-day share price return of 51.58% alongside a 1-year total shareholder return of 86.07%. This suggests investors are reacting to both the new lymphoma data and earlier partnerships with Susan G. Komen and Angiex as signs that clinical evidence and commercial reach are broadening.

Capitalize on the momentum around Natera by comparing what you are seeing here against a curated group of resilient healthcare and diagnostics peers in our 83 resilient stocks with low risk scores.

After a run that has turned a US$328.18 share price into a talking point, the real question for Natera is whether the heavy lifting is already reflected in the price or whether the valuation still leaves room for more.

Most Popular Narrative: 16.3% Overvalued

The most followed narrative pegs Natera at a fair value of $282.14, which sits well below the latest $328.18 close and frames the current enthusiasm as relatively rich.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 187.7x on those 2029 earnings, up from -166.2x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.

Read the complete narrative.

This raises questions about the revenue curve and margin shift that such a valuation assumes. The narrative leans heavily on rising profitability, faster top line expansion and a rich future earnings multiple built on that profile. It is worth examining how those moving pieces come together in a single fair value number.

Result: Fair Value of $282.14 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the narrative can weaken if reimbursement tightens or if rivals in oncology and prenatal testing capture more share than Natera currently enjoys.

Find out about the key risks to this Natera narrative.

Another Way To Look At Natera’s Valuation

The analyst narrative paints Natera as 16.3% overvalued at $328.18 versus a fair value of $282.14, yet the SWS DCF model points in the opposite direction and flags the stock as trading about 45.4% below an estimated future cash flow value of $600.57. Which lens feels more realistic for the risk you are willing to take?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the tone of the Natera debate feels divided, use that tension as a prompt to check the underlying numbers yourself and move quickly from headline to conviction. To see what the current optimism is anchored to, review the 3 key rewards.

Looking for more Natera-like investment ideas?

Do not stop with Natera. Broaden your watchlist with a few focused stock pools that match different risk and income goals using the Simply Wall Street Screener.

• Target steadier balance sheets and cash flows by working through a curated list of solid balance sheet and fundamentals (24 results) that filters for financial resilience.
• Hunt for mispriced opportunities by scanning a focused 49 high quality undervalued stocks that blends quality markers with valuation checks.
• Build a cash return stream by reviewing a hand picked 6 dividend fortresses that screens for higher yields alongside business strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com